Vice President & Global Head, Commercial Strategy Development @ PPD
Vice President Global Product Development, Haematology/Oncology & Global Medical Strategy Liaison @ PPD
Vice President Global Medical Affairs, Haematology/Oncology at Cell Therapeutics, Inc. @ Cell Therapeutics, Inc.
Ph.D., Clinical Cancer Medicine (Clinical Studies) @
A senior industry executive with a creative and entrepreneurial attitude, having worked on >10 Oncology compounds including Marketing Authorisation Applications (MAAs) and reimbursement submissions, excellent position to capitalise on my scientific, global medical affairs, clinical R&D, regulatory and people management expertise, significantly enhanced through exposure to both NHS/academic and commercial industry environments. Highly motivated, and along with
A senior industry executive with a creative and entrepreneurial attitude, having worked on >10 Oncology compounds including Marketing Authorisation Applications (MAAs) and reimbursement submissions, excellent position to capitalise on my scientific, global medical affairs, clinical R&D, regulatory and people management expertise, significantly enhanced through exposure to both NHS/academic and commercial industry environments. Highly motivated, and along with tremendous enthusiasm, determination and an excellent attitude related to delivering transformational solutions that prolong and improve cancer patient's lives.
Successful track record of leadership and influence at Board level with significant change management experience as well as demonstrable experience of directing programmes across organisational boundaries and within large complex multidisciplinary professional organisations. This has also included functioning within global roles where an acute appreciation of local rules, regulations, needs and cultural differences was a necessity for continued success. Financially accountable through focusing on cost-effective deliverables, developing cohesive financial plans, and tracking budget variances, thereby ensuring a positive P/L in all business ventures and endeavours. Thorough understanding of the potential of technology, market and business models, attracting high profile international investors and venture capital financing.
Vice President Global Medical Affairs, Haematology/Oncology at CTI @ Built and commercialised the European business division for CTI at a Vice President, senior managerial level.
Established the vision, strategy and Medical Affairs plan to maximise patient outcomes. Provided leadership in awareness and positioning of the disease vision, publication planning, disease registries, advisory boards, medical field programme, training programmes, investigator-sponsored research and specific scientific initiatives with international disease experts.
Clearly communicated key data and information to a broad range of customers including: KOLs, guideline developers, research consortiums and business partners to represent CTI and the product portfolio.
As a result, appointed as co-Chair of Strategic Alliance Joint Steering Committee (JSC).
Responsible for leading the Medical Affairs franchise team, consisting of members from Medical Research, Scientific Communications and Regional Medical Directors.
Work in close partnership with the commercial franchise leaders providing leadership to global cross functional, medico-marketing team.
Develop and maintain relationships with key global disease experts through Advisory Boards, Professional Associations and Meetings, Trade Exhibits etc., to achieve CTI’s corporate and development objectives.
Provide scientific input in guidance of strategy development for Pixantrone and other pipeline products including Pacritinib and Tosedostat.
Provide medical and strategic input to the registration and development strategy for marketed and pipeline products as well as New Business Development opportunities.
Responsible for establishing, developing and managing relationships with patient advocacy stakeholder groups that champion patient access to appropriate information and treatment.
Actively contributing to the clinical definition, development, implementation and maintenance of product pricing, reimbursement and market access strategies across Europe including NICE, G-BA (IQWiG), AIFA and HAS. From September 2012 to Present (3 years 1 month) LondonGlobal Clinical & Medical Affairs Leader, Oncology R&D @ Unique dual role that spanned across Global Medical Affairs and R&D for the clinical development and launch of key Oncology assets for Janssen.
Organised, Chaired and Presented at Advisory Boards that encompassed both Medical Affairs and R&D strategic activities.
Extensive network of Global Clinical Investigators, KOLs, Medical Directors and Scientific Experts.
Medical oversight of global Oncology clinical trials across all phases of drug development and the interpretation and reporting of data, and the preparation of oral and written results to Senior Management, Regulatory Authorities and other key stakeholders. From March 2007 to September 2012 (5 years 7 months) European Regulatory Leader (Oncology Products) @ Contact point with the EMA and interacting with regional regulatory agencies.
Within the context of the global strategy, determining appropriate regional strategy and content for key HA submission meetings.
Member of the European Commercial Team for VELCADE®. Contributions to Marketing Excellence and Segmentation exercise, Competitive Intelligence, and Communications strategies. From November 2004 to March 2007 (2 years 5 months) Director, Developmental Studies @ Management of the biotherapeutic drug development of the lead Cell Vaccine for prostate cancer, Onyvax-P (Preclinical and Phase I through to Phase II).
Technology transfer/market research (including active contribution to in-licensing, strategic alliances, out-licensing, due diligence relating to intellectual property and patents) and commercial awareness gained in the biotechnology industry. From May 2001 to October 2004 (3 years 6 months) Clinical & Scientific Director, Laboratory of Cellular Therapeutics @ Core member of the Bone Marrow Transplant cross-functional Clinical Team.
Separation, manipulation and banking of Peripheral Blood Stem Cells, Bone Marrow, Cord Blood, and Donor Leukocyte Infusions including depletion of T-lymphocytes for infusion at time of transplant or cryopreservation.
Clinical-grade graft engineering, including CD34+ haemopoietic stem cell enrichment.
Therapeutic applications utilising Dendritic Cells.
Immunotherapy of epithelial ovarian carcinoma with autologous activated macrophages (MAK) and humanised monoclonal anti-Her-2/neu bispecific antibodies (hMab).
Development of methods for the detection, enumeration and characterisation of contaminating tumour cells in bone marrow, peripheral venous blood and haematopoietic grafts from patients with epithelial malignancies, with a view of monitoring the efficiency of positive selection and/or ex-vivo purging procedures, prior to transplantation.
Extensive experience of clinical trial design, clinical data management/analysis, preparation of protocols and SOPs, and maintenance of detailed clinical laboratory databases and records.
Involvement in additional immunotherapy/gene transfer programmes for acute leukaemia. From April 1994 to April 2001 (7 years 1 month)
Fellow of the Royal College of Pathologists (FRCPath), London, UK @ Royal Free and University College Medical School, (Royal Free Campus), University of LondonPh.D., Clinical Cancer Medicine (Clinical Studies) @ UCL From 1997 to 2001 M.Sc., Applied Clinical Haematology @ University of Westminster From 1992 to 1994 FIBMS, Fellow of the Institute of Biomedical Sciences @ Academic Department of Haematology, Royal Free Hospital, London From 1992 to 1994 B.Sc. (Hon), Medical Biochemistry (First Class) @ King's College London From 1988 to 1991 Dr. Theocharous is skilled in: Oncology, Clinical Development, Clinical Research, Medical Affairs, Pharmaceutical Industry, Drug Development, Key Opinion Leaders, Clinical Trials, Biotechnology, Hematologic Malignancies, Medical Directors, Commercialization, Strategic Alliances, Business Development, Market Access, Pricing, Reimbursement, Cross Functional..., Cancer, Drug Discovery, Lifesciences, Immunology, Biopharmaceuticals, Hematology, Medicine, R&D, Stem Cells, Pharmacovigilance, Transplant, Therapeutic Areas, Infectious Diseases, Medical Research, Medical Writing, GCP, CTMS, CRO, Translational Medicine, Biomarkers, Pharmacology, Regulatory Submissions, Diabetes, Neurology, Dermatology, Regulatory Affairs, ICH-GCP, Health Economics, Gastroenterology, Clinical Monitoring, Rheumatology, Sop
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension